Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience

Area of Science:

• Biochemistry
• Analytical Chemistry
• Clinical Diagnostics

Background:

• Mass spectrometry (MS) platforms have emerged as powerful tools for profiling native peptides and proteins, offering significant clinical potential.
• Early Surface-Enhanced Laser Desorption/Ionization (SELDI) systems faced challenges with reproducibility and analytical robustness, limiting their clinical application for biomarker qualification.
• Despite these limitations, MS-based peptide profiling remains an active area of research for developing novel diagnostic and prognostic markers.

Purpose of the Study:

• To provide a concise overview of the available data on the performance and analytical robustness of various peptide profiling platforms.
• To critically evaluate the analytical performance metrics, including reproducibility, stability, interference, quantification limits, and inter-laboratory variability.
• To discuss the challenges and potential improvements for MS-based peptide profiling in clinical settings, using the CE-MS platform as a case study.

Main Methods:

• Review of existing literature on the analytical performance and robustness of mass spectrometry platforms for peptide profiling.
• Detailed examination of data related to short-term and intermediate repeatability, stability, interference, and limit of detection for peptide quantification.
• Case study analysis using the development of a 273-peptide marker for chronic kidney disease (CKD) to illustrate practical challenges and solutions.

Main Results:

• The article highlights that while MS platforms have advanced, issues with reproducibility and analytical robustness persist, impacting clinical implementation.
• Data on the capillary electrophoresis-mass spectrometry (CE-MS) platform demonstrates variability in performance metrics such as repeatability, stability, and quantification capabilities.
• The development of a CKD biomarker revealed practical hurdles in achieving robust and reproducible peptide profiling across different settings.

Conclusions:

• Mass spectrometry platforms require rigorous analytical validation, including assessment of reproducibility and robustness, before clinical implementation.
• Comparative studies evaluating the clinical performance and impact of different MS platforms that pass analytical validation are essential.
• Further research and standardization are needed to overcome the limitations of MS-based peptide profiling and fully realize its clinical potential for biomarker discovery and application.